Top-Rated StocksTop-RatedNASDAQ:ROIV Roivant Sciences (ROIV) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free ROIV Stock Alerts $10.54 -0.30 (-2.77%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$10.37▼$10.9350-Day Range$9.87▼$11.8052-Week Range$6.97▼$13.24Volume65.65 million shsAverage Volume6.57 million shsMarket Capitalization$8.49 billionP/E Ratio2.03Dividend YieldN/APrice Target$16.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Roivant Sciences alerts: Email Address Roivant Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside56.5% Upside$16.50 Price TargetShort InterestBearish6.55% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.71Based on 9 Articles This WeekInsider TradingSelling Shares$34.21 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.36) to ($1.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.88 out of 5 starsMedical Sector252nd out of 938 stocksPharmaceutical Preparations Industry106th out of 417 stocks 4.5 Analyst's Opinion Consensus RatingRoivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.50, Roivant Sciences has a forecasted upside of 56.5% from its current price of $10.54.Amount of Analyst CoverageRoivant Sciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.55% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Roivant Sciences has recently increased by 14.01%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRoivant Sciences does not currently pay a dividend.Dividend GrowthRoivant Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ROIV. Previous Next 3.2 News and Social Media Coverage News SentimentRoivant Sciences has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Roivant Sciences this week, compared to 5 articles on an average week.Search InterestOnly 10 people have searched for ROIV on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows17 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 42% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Roivant Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,208,694.00 in company stock.Percentage Held by InsidersOnly 4.60% of the stock of Roivant Sciences is held by insiders.Percentage Held by Institutions64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Roivant Sciences are expected to grow in the coming year, from ($1.36) to ($1.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Roivant Sciences is 2.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 148.82.Price to Earnings Ratio vs. SectorThe P/E ratio of Roivant Sciences is 2.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 275.18.Price to Book Value per Share RatioRoivant Sciences has a P/B Ratio of 5.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Roivant Sciences Stock (NASDAQ:ROIV)Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Read More ROIV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ROIV Stock News HeadlinesMarch 26, 2024 | msn.comViking Therapeutics gains on early data for oral weight loss therapyMarch 26, 2024 | msn.com'Some people have principles': Internet divided as Vivek Ramaswamy predicts NY ruling against Trump could energize key voter groupMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 26, 2024 | americanbankingnews.comRoivant Sciences' (ROIV) Buy Rating Reaffirmed at Truist FinancialMarch 26, 2024 | americanbankingnews.comAnalyzing Roivant Sciences (NASDAQ:ROIV) and Relief Therapeutics (OTCMKTS:RLFTF)March 14, 2024 | fr.investing.comL'objectif de cours de Roivant Sciences relevé à 16$ par Goldman SachsMarch 13, 2024 | edition.cnn.comTravere Therapeutics, Inc.March 13, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Roivant Sciences (ROIV)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.February 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Roivant Sciences: Undervaluation and Promising Pipeline Drive Positive OutlookFebruary 15, 2024 | finance.yahoo.comDo You Think the Management of Roivant Sciences (ROIV) Can Create Value?February 14, 2024 | msn.comRoivant Sciences Ltd. (NASDAQ:ROIV) Q3 2023 Earnings Call TranscriptFebruary 14, 2024 | markets.businessinsider.comHold Rating on Roivant Sciences Amidst Mixed Performance and Strategic FocusFebruary 14, 2024 | markets.businessinsider.comThe Analyst Landscape: 4 Takes On Roivant SciencesFebruary 14, 2024 | finance.yahoo.comRoivant Sciences Third Quarter 2024 Earnings: Beats ExpectationsFebruary 14, 2024 | markets.businessinsider.comBuy Rating for Roivant Sciences: Solid Sales and Promising Clinical DevelopmentsFebruary 14, 2024 | realmoney.thestreet.comRoivant Sciences price target lowered by $2 at Goldman Sachs, here's whyFebruary 14, 2024 | finance.yahoo.comQ3 2024 Roivant Sciences Ltd Earnings CallFebruary 13, 2024 | finance.yahoo.comRoivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business UpdateFebruary 12, 2024 | msn.comRoivant Sciences Q3 2024 Earnings PreviewFebruary 10, 2024 | finance.yahoo.comRoivant Sciences Ltd President & COO Eric Venker Sells 96,950 SharesFebruary 1, 2024 | marketwatch.comRoche Expected to Report Lower Sales, Profit -- Earnings PreviewJanuary 30, 2024 | finance.yahoo.comRoivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024January 17, 2024 | usnews.comMost Iowa Republican Caucus-Goers Say Trump Fit to Be President if ConvictedJanuary 17, 2024 | forbes.comHow Vivek Ramaswamy Got Richer While Pumping Millions Into Failed Presidential CampaignJanuary 15, 2024 | msn.comIowa Caucus live updates: Donald Trump, Nikki Haley and other Republican hopefuls make their final pushJanuary 15, 2024 | msn.comTrump's Rare Praise for DeSantis Hours Before Iowa Caucus StartsSee More Headlines Receive ROIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today3/28/2024Fiscal Year End3/31/2024Next Earnings (Estimated)6/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ROIV CUSIPN/A CIK1635088 Webroivant.com Phone44-20-7400-3347FaxN/AEmployees904Year FoundedN/APrice Target and Rating Average Stock Price Target$16.50 High Stock Price Target$23.00 Low Stock Price Target$12.00 Potential Upside/Downside+56.5%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$5.20 Trailing P/E Ratio2.03 Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,009,030,000.00 Net Margins3,624.14% Pretax Margin3,461.24% Return on Equity-33.38% Return on Assets-26.06% Debt Debt-to-Equity Ratio0.06 Current Ratio27.79 Quick Ratio27.79 Sales & Book Value Annual Sales$61.28 million Price / Sales138.60 Cash FlowN/A Price / Cash FlowN/A Book Value$2.11 per share Price / Book5.00Miscellaneous Outstanding Shares805,850,000Free Float768,777,000Market Cap$8.49 billion OptionableOptionable Beta1.37 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Matthew Gline (Age 40)CEO & Director Comp: $1.77MDr. Eric Venker M.D. (Age 37)Pharm.D., President & COO Comp: $1.28MDr. Mayukh Sukhatme M.D. (Age 48)President, Chief Investment Officer & Director Comp: $1.72MMr. Richard Pulik (Age 45)Chief Financial Officer Ms. Rakhi Kumar (Age 44)Chief Accounting Officer Dr. Huafeng Xu Ph.D.Chief Technology OfficerMr. Josh ChenGeneral CounselMs. Kelly GraffHead of PeopleMs. Marianne L. Romeo (Age 56)Head of Global Transactions & Risk Management Mr. Alex GasnerExecutive Vice President of Roivant HealthMore ExecutivesKey CompetitorsViking TherapeuticsNASDAQ:VKTXElanco Animal HealthNYSE:ELANCerevel TherapeuticsNASDAQ:CEREAscendis Pharma A/SNASDAQ:ASNDJazz PharmaceuticalsNASDAQ:JAZZView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 1,473,085 shares on 3/11/2024Ownership: 0.878%Wellington Management Group LLPSold 1,202,560 shares on 3/5/2024Ownership: 1.693%Virtu Financial LLCBought 12,118 shares on 2/26/2024Ownership: 0.002%Eventide Asset Management LLCSold 546,362 shares on 2/20/2024Ownership: 0.142%Public Employees Retirement System of OhioBought 7,459 shares on 2/16/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions ROIV Stock Analysis - Frequently Asked Questions Should I buy or sell Roivant Sciences stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ROIV shares. View ROIV analyst ratings or view top-rated stocks. What is Roivant Sciences' stock price target for 2024? 10 Wall Street analysts have issued twelve-month target prices for Roivant Sciences' shares. Their ROIV share price targets range from $12.00 to $23.00. On average, they predict the company's stock price to reach $16.50 in the next year. This suggests a possible upside of 56.5% from the stock's current price. View analysts price targets for ROIV or view top-rated stocks among Wall Street analysts. How have ROIV shares performed in 2024? Roivant Sciences' stock was trading at $11.23 at the beginning of the year. Since then, ROIV shares have decreased by 6.1% and is now trading at $10.54. View the best growth stocks for 2024 here. When is Roivant Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 26th 2024. View our ROIV earnings forecast. How were Roivant Sciences' earnings last quarter? Roivant Sciences Ltd. (NASDAQ:ROIV) released its quarterly earnings data on Tuesday, February, 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.07. The business earned $37.14 million during the quarter, compared to the consensus estimate of $30.72 million. Roivant Sciences had a net margin of 3,624.14% and a negative trailing twelve-month return on equity of 33.38%. What ETFs hold Roivant Sciences' stock? ETFs with the largest weight of Roivant Sciences (NASDAQ:ROIV) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Products ETF (BBP), Direxion Moonshot Innovators ETF (MOON), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), Invesco Dorsey Wright Momentum ETF (PDP) and First Trust Nasdaq Pharmaceuticals ETF (FTXH). Who are Roivant Sciences' major shareholders? Roivant Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Viking Global Investors LP (8.63%), Rubric Capital Management LP (2.36%), Wellington Management Group LLP (1.69%), Vanguard Group Inc. (0.88%), Vanguard Group Inc. (0.88%) and Price T Rowe Associates Inc. MD (0.47%). Insiders that own company stock include Eric Venker, Financial Lp Qvt, Global Investors Lp Viking, Keith S Manchester, Matthew Gline, Pharma Technologies Ltd Dexcel, Rakhi Kumar, Richard Pulik, Sciences Ltd Roivant, Svf Investments (Uk) Ltd and Vivek Ramaswamy. View institutional ownership trends. How do I buy shares of Roivant Sciences? Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ROIV) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.